Furthermore, the inflammatory response of COVID-19 exhibits a similar macrophage-derived cytokine profile as hemophagocytic lymphohistiocytosis (18), which is responsive to the selective JAK1/JAK2 inhibitor ruxolitinib (19, 20). This evidence concerns the gene JAK2 and COVID-19.